The retail segment posted the highest growth, which was evaluated as being 23 percent higher compared to Jan. – March 2008, up to 1.73 billion lei. Retail was followed by the hospital segment, with a rise of 19 percent, up to 255 million lei, according to a Cegedim Romania report, taken over by Financiarul daily on Tuesday.
As reported to the euro, the domestic pharmaceutical market growth in the first three months of 2009 accounted for 6 percent. Romania’s pharmaceutical market was evaluated at 466.5 million euros in the first quarter of 2009. The retail segment advanced by 6.4 percent, to 406.8 million euros, and the hospital segment by 3.2 percent, to 59.7 million euros, Cegedim study reports.
As for the main players on the pharmaceutical market, Swiss Hoffmann la Roche producer is in the leading position, with sales of 165.1 million lei (575.2 million lei in April 2008 – March 2009) and a market share of 7.6 percent.
The following two spots are taken by French Sanofi Aventis Group, with sales of 136 million lei and a weight of 7.1 percent of the total and by British GlaxoSmithKline producer, with receipts of 138 million lei and a market share of 6.8 percent.
Swiss Novartis Group ranks fourth, with sales of 122.2 million lei in the first quarter and a market share of 6.4 percent, followed by Servier, with 5.9 percent of the market and sales of 116.5 million lei and by Pfizer, with 5.2 percent. Ranbaxy, Zentiva, Astra Zeneca and Antibiotice Iasi account for 13.7 percent of the market.
Johnson&Johnson, Actavis, Solvay and Gedeon Richter have the lowest market shares, ranging between 2.5 percent and 1.5 percent.
In 2009, Cegedim estimates an average growth of 10 percent of its medicine sales calculated in lei, but an average decline of 3 percent in euros.
In 2008, according to Cegedim data, the pharmaceutical sector value stood at 1.9 billion euros, or 7.16 billion lei.